are required to elucidate the precise role of SOPOC during ERCP.

**IDDF2018-ABS-0147**

**EFFICACY AND SAFETY OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY IN NONAGENARIANS: A COMPARATIVE STUDY**

1Zheng Jin*, 2Xiaofeng Zhang. 1Hangzhou Geriatric Hospital, Hangzhou First People’s Hospital Group, Hangzhou, China; 2Department of Gastroenterology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou, China

10.1136/gutjnl-2018-IDDFabstracts.221

**Background** Little information is available on the long-term outcome of endoscopic retrograde cholangiopancreatography (ERCP) for pancreatobiliary diseases in nonagenarians (≥90 years). This study was to evaluate the efficacy and the safety of ERCP in the treatment of patients 90 years of age and older.

**Methods** Consecutive nonagenarian patients who underwent therapeutic ERCP between May 2005 and January 2017 at a tertiary-care centre were retrospectively reviewed. One hundred and fifty-five patients aged 90 years and older were identified (Group A). Matched by gender and ratio 1:2, 310 patients under 65 years were assigned to control group (Group B). Clinical features, endoscopic findings, interventions, long-term results of ERCP for a mean follow-up of 12 months were assessed and compared between the two groups.

**Results** Group A had a higher incidence of concomitant diseases, acute cholangitis, and acute cholecystitis, as compared to group B (p<0.05). There was no significant difference in the technical success rate and procedure time between the two groups. The rate of post-ERCP pancreatitis was significantly less in the group A compared to the group B (p<0.05). The occurrence of haemorrhage, perforation, and other complications was not statistically different among the two groups. The mortality directly related to the ERCP procedure was zero.

**Conclusions** ERCP is safe and effective for the management of pancreatobiliary diseases in patients aged 90 years or older.

**IDDF2018-ABS-0150**

**RISK OF HEPATOCELLULAR CANCER AND DEATH/TRANSPLANT BETWEEN INACTIVE HEPATITIS B AND HBEAG-NEGATIVE CHRONIC HEPATITIS B WITH ANTIVIRAL AGENTS**

1Gwang Hyeon Choi*, 1Gi-Ae Kim, 1Jonggi Choi, 2Seungbong Han, 1Young-Suk Lim. 1Asan Medical Center, Korea, South; 2Gachon University, Korea, South

10.1136/gutjnl-2018-IDDFabstracts.222

**Background** Nucleos(t)ide analogues (NUCs) treatment in HBe-negative chronic hepatitis B (CHB) patients would maintain a similar virologic and biochemical state compared to inactive hepatitis. And, sustained reduction of hepatitis B viral load by NUCs is helpful in lowering the risk of HCC. The purpose of this study was to evaluate the cumulative incidence of hepatocellular carcinoma (HCC) and death/transplantation in patients with inactive patients compared with HBeAg-negative CHB patients treated with NUCs.

**Methods** We performed a retrospective analysis of data from 3202 consecutive adult patients with non-cirrhotic CHB, inactive hepatitis (n=2,677) and HBeAg-negative CHB treated with NUCs between January 2000 and December 2013. Data were collected from patients for median 5.4 years and analysed by a multivariable Cox proportional hazards model for the entire cohort and propensity score-matched cohort.

**Results** During the study period, 127 (4.0%) developed HCC, 156 (4.8%) died or received transplantation. The annual risk of developing HCC and death/transplantation of inactive
hepatitis and NUC treated HBeAg-negative hepatitis were 0.49% vs. 1.60% (hazard ratio [HR], 3.36; 95% confidence interval [CI], 1.20–4.82; p<0.001) and 0.77 vs. 8.00 (HR, 1.16, 95% CI 0.76–1.78, p<0.61), respectively. Multivariable analyses showed that compared with treated group, inactive hepatitis was associated with a significantly lower risk of HCC (HR, 0.43; 95% CI, 0.29–0.64; p<0.001) but a similar risk of death/transplantation (HR, 0.95; 95% CI, 0.61–1.49; p=0.82). In the propensity score-matched cohort (469 Pairs), inactive hepatitis was associated with a significantly lower risk of NUC treated HBeAg-positive hepatitis and NUC treated HBeAg-negative hepatitis were 0.87% (95% CI: 0%–1.4%); p=0.54). And the proportion of NUC treatment in inactive hepatitis was actually low (Estimated annual rate=0.87%).

Conclusions Inactive hepatitis develops significantly fewer HCCs compared to HBeAg-negative CHB hepatitis treated with NUCs with similar biochemical and virologic profile. In the NUC era, inactive hepatitis could be still evaluated as stable enough in the area where genotype C is dominant.

**IDDF2018-ABS-0154**

**VIROLOGICAL AND CLINICAL OUTCOMES AFTER CESSION OF NUCLEOS(T)IDE ANALOGUE THERAPY FOR CHRONIC HEPATITIS B – A PROSPECTIVE COHORT STUDY IN CENTRAL TAIWAN**


1. Taichung Veterans General Hospital, Taiwan; 2. Changhua Christian Hospital, Taiwan; 3. Show Chwan Memorial Hospital, Taiwan; 4. Chun-Hua Hospital, Ministry of Health and Welfare, Taiwan; 5. Show Chwan Memorial Hospital, Chang Bing Branch, Taiwan; 6. China Medical University Hospital, Taiwan; 7. Chang Shan Medical University Hospital, Taiwan; 8. Cheng Ching General Hospital, Chang Kang Branch, Taiwan; 9. Tung’s Taichung MetroCity Hospital, Taiwan; 10. Taichung Tzu Chi Hospital, Taiwan

10.1136/gutjnl-2018-IDDFabstracts.223

**Background** Hepatitis B virus (HBV) relapse is a practical issue after nucleos(t)ide analogue (NA) therapy discontinuation in chronic hepatitis B (CHB). However a prospective multi-centre study remains lacking. The aim of this study was to prospectively investigate virological and clinical outcomes after NA therapy.

**Methods** CHB patients, who discontinued tenofovir disoproxil fumarate (TDF) or entecavir (ETV) therapy based on the NA stopping guidelines, were prospectively recruited from January 2015 to January 2018. Patients with liver cirrhosis, active malignancies, hepatitis C virus, hepatitis D virus or human immunodeficiency virus coinfection, liver transplantation history, immune disorders, a history of NA therapy other than TDF or ETV, or a follow-up period of fewer than 4 weeks were excluded. Serum HBV DNA and quantitative hepatitis B surface antigen (qHBsAg) levels were measured every 3 months. Both cumulative incidences of and hazard ratios (HRs) for the predictors of HBV relapse were analysed.

**Results** Totally, 178 patients (40 HBeAg-positive and 138 HBeAg-negative prior to NA therapy) were enrolled for this analysis (98 TDF and 80 ETV users), and the median follow-up period was 10.6 (interquartile range [IQR]: 5.6–7.2) months. The cumulative incidences of virological (VR) and clinical relapse (CR) in 2 years were 59.5% (95% confidence interval [CI]: 50.6%–68.3%) and 49.0% (95% CI: 34.0%–65.0%), respectively. Moreover, the cumulative incidences of severe hepatitis flare (ALT >500 IU/L) and liver
decompensation were 11.8% (95% CI: 3.4%–19.6%) and 1.4% (95% CI: 0%–3.3%), respectively. No patient died of liver disease. In multivariable analysis, qHBsAg >100 IU/mL at the end of therapy was an independent risk factor of VR (HR 2.47, 95% CI: 1.30–4.70) and of CR (HR 3.16, 95% CI: 1.25–7.89), respectively. TDF users initially demonstrated a faster pattern of HBV relapse when compared to ETV users, but the relapse rates were not significantly different in 2 years.

**Conclusions** In this study for non-cirrhotic patients, HBV relapse was common after cessation of NA therapy, and serum qHBsAg can be used as a predicting marker. A longer study period is essential for investigating long-term outcomes.

**IDDF2018-ABS-0155**

**A PROSPECTIVE CROSS-SECTIONAL STUDY ON THE PREVALENCE AND FACTORS ASSOCIATED WITH SEROPROTECTION AFTER PRIMARY SERIES OF HEPATITIS B VACCINATION**

Adrienne Michelle Lu*, Philippine Children’s Medical Center, Philippines

10.1136/gutjnl-2018-IDDFabstracts.224

**Background** Hepatitis B infection is a vaccine-preventable condition that is commonly asymptomatic in children and unrecognised until complications such as cirrhosis and hepatocellular carcinoma develop. Identifying patients at risk for Hepatitis B infection despite universal vaccination will help improve the immunisation programme. The objective is to determine the prevalence and factors associated with seroprotection among children 3 months to 18 years old with complete primary Hepatitis B vaccination series.

**Methods** This is a prospective cross-sectional study among children 3 months to 18 years old seen at Philippine Children’s Medical Centre (PCMC) charity and private outpatient clinic from March-June 2017 with immunisation record of complete Hepatitis B immunisation. Children who are immunocompromised, those who received vaccine within four weeks from the time of the conduct of the study and those who received booster doses were excluded. Serologic determination of antibody to Hepatitis B surface antigen (Anti-HBs), total antibody to Hepatitis B core antigen (Total Anti-HBc) and Hepatitis B surface antigen (HBsAg) were done. Demographic, social and clinical data were correlated with reactivity to Anti-HBs (≥10 mIU/ml), Total Anti-HBc and HBsAg serologic tests.

**Results** Among 110 subjects from different age groups, 52% had seroprotective Anti-HBs levels (≥10 mIU/ml), with the highest noted among infants (3 months–2 years) at 82%, followed by 41% from the childhood group (3–9 years) and 26% from the adolescent group (10–18 years). Seventy-four percent seroprotection rate was noted among subjects with <5 years interval from vaccination, 26% in cases after 5–10 years, and 38% at more than 10 years after vaccination with a significant difference on multilogistic regression (p value 0.000/0.020). None of the other factors including gender, geographic area, age at first dose, schedule, type and place of vaccine were significantly associated with seroprotection.

**Conclusions** Fifty-two percent of patients among different age groups were seroprotected, with the highest among children 3 months–2 years old. Seroprotection was significantly associated with the interval year after vaccination demonstrated at less than 50%, 5 years and beyond post-vaccination.